GlassScriptPhysician profile
Daniel J Hopson
NPI 1265476154
$707.67
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $50.34 · 2022: $28.18 · 2023: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $169.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $144.32 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $122.13 | 2019 | |
| Abbott Laboratories | $119.30 | 2023 | Infinity |
| Abbvie INC. | $61.46 | 2019-2023 | |
| Amgen INC. | $47.97 | 2019 | |
| Livanova USA, INC. | $42.32 | 2019 | |
| Novartis Pharmaceuticals Corporation | $36.09 | 2019 | |
| Horizon Therapeutics Plc | $29.90 | 2023 | Uplizna |
| Kyowa Kirin, INC. | $21.58 | 2019 | |
| Amneal Pharmaceuticals LLC | $20.36 | 2020 | |
| Alnylam Pharmaceuticals INC. | $19.30 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.16 | 2019 | |
| Upsher-Smith Laboratories LLC | $15.12 | 2019 | |
| Allergan, INC. | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hopson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.